Translational research funding boost
24 November 2017
A prestigious award from the National Health and Medical Research Council (NHMRC) has been presented to Associate Professor Rachael Morton, an Investigator at Melanoma Institute Australia and Research Theme Leader for Society, Policy and Economics.
The NHMRC Translating Research Into Practice (TRIP) Fellowship aims to support future leaders to undertake projects focused on translating evidence into practice that will have a deep impact on health care.
The funding will help researchers at Melanoma Institute Australia continue their ground-breaking research in melanoma that will change the way melanoma treatment is assessed in the future.
A/Prof Morton will use the funding to incorporate Patient Reported Outcome Measures (PROMs) into clinical quality registries.
“PROMs are an important method to better understand outcomes that matter to patients and include any metric assessing health, illness or health care benefits from the patient’s perspective, such as a questionnaire,” explains A/Prof Morton. “In the clinic, PROMs have the potential to highlight relevant symptoms and changes in symptoms, promote patient engagement in their treatment and improve patient outcomes.”
“Instruments measuring the patient’s perspective have been available for decades; however their incorporation into routine clinical practice has until recently been slow. We hope to facilitate this process.”
The work from this Fellowship will help integrate PROMs into the new Australian Clinical Outcomes Register for Melanoma, also known as the Big Data for Melanoma project, which has been made possible by collective fundraising efforts from the national Melanoma March campaign.
Innovation is helping to prevent melanoma developing in the first place.
Research from MIA is changing the way melanoma is managed worldwide and improving patient survival. Here are a few of our key highlights from this year.
A prestigious Fellowship has been awarded to fund research that will change the way melanoma treatment is assessed in the future.
New research from MIA has been published that forms the basis of the updated international guidelines for staging melanoma.
Professor William McCarthy AM has been awarded the Tom Reeve Award for Outstanding Contributions to Cancer Care.
Leading researchers from MIA have been acknowledged with three prestigious awards for excellence in melanoma research.
New research shows that patients who are more likely to respond to immunotherapy treatment have a greater diversity in their gut bacteria.
MIA's epidemiologist explains her new research on how country of residence should be considered when identifying melanoma risk.
Congratulations to our Conjoint Medical Directors, Professor Georgina Long and Professor Richard Scolyer, who have today been announced as Fellows of the Australian Academy of Health and Medical Sciences.
New research shows potentially deadly UV damage can appear decades earlier than you think.
Early lymph node check is saving lives in melanoma patients
We are pleased to announce that A/Prof Anne Cust is the new President of the Australasian Epidemiological Association.
More than $3.5 million in competitive funding grants have been awarded to MIA's researchers.
The ESMO conference provided a platform for announcing a number of key melanoma research findings - including practice-changing research from MIA.
Australian researchers have successfully trialled a combination of new treatments to prevent melanoma from spreading to distant organs.
A new treatment that combines an antibody with a cancer-killing virus improves outcomes for patients with advanced melanoma, an international clinical trial has shown.
It feels like groundhog day - another reality TV show, another batch of blatantly sunburnt contestants.
Wouldn’t it be great if your doctor could know if you would respond to treatment before you even had it?
In our latest research update we showcase research in survival estimates, uncover biomarkers, and reveal practice-changing research in surgery and medical oncology.